Evolent Health, Inc – Consensus Indicates Potential 28.1% Upside

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Evolent Health, Inc with ticker code (EVH) now have 7 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 55 and 37 calculating the average target price we see 46.14. Now with the previous closing price of 36.02 this indicates there is a potential upside of 28.1%. There is a 50 day moving average of 32.62 and the 200 moving average now moves to 28.75. The market cap for the company is $3,446m. Find out more information at: https://www.evolenthealth.com

The potential market cap would be $4,414m based on the market concensus.

Evolent Health, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search